Drugs Containing Excipient (Inactive Ingredient) ALCOHOL

Branded drugs containing ALCOHOL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	AMYVID	florbetapir f 18	0002-1200	ALCOHOL	2027-04-30
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1210	ALCOHOL	2032-05-26
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1220	ALCOHOL	2032-05-26
Eli Lilly and Company	RETEVMO	selpercatinib	0002-3977	ALCOHOL	2038-04-10
ER Squibb & Sons LLC	REYATAZ	atazanavir	0003-3624	ALCOHOL
Pharmacia & Upjohn Company LLC	PROSTIN	alprostadil	0009-0215	ALCOHOL
Pharmacia & Upjohn Company LLC	PROSTIN	alprostadil	0009-3169	ALCOHOL

Generic drugs containing ALCOHOL excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	florbetapir f 18	0002-1200	ALCOHOL
Eli Lilly and Company	flortaucipir f-18	0002-1210	ALCOHOL
Eli Lilly and Company	flortaucipir f-18	0002-1220	ALCOHOL
Eli Lilly and Company	selpercatinib	0002-3977	ALCOHOL
ER Squibb & Sons LLC	atazanavir	0003-3624	ALCOHOL
Pharmacia & Upjohn Company LLC	alprostadil	0009-0215	ALCOHOL
Pharmacia & Upjohn Company LLC	alprostadil	0009-3169	ALCOHOL

Pharmaceutical Excipient Alcohol Market Dynamics and Financial Trajectory

Last updated: August 12, 2026

Pharmaceutical excipient alcohol is primarily ethanol, also called ethyl alcohol. Its market is mature, fragmented and highly exposed to feedstock, energy, regulatory and logistics costs. Demand is resilient because ethanol is used in oral liquids, topical products, disinfectants, extraction processes, coatings and drug-delivery systems. Margin expansion depends less on pharmaceutical volume growth than on product-grade segmentation, denaturation controls, supply qualification and the ability to pass through corn, sugar, natural-gas and freight costs.

The pharmaceutical-grade segment is small relative to the global fuel and industrial ethanol markets. Public companies rarely report pharmaceutical ethanol as a separate revenue line. Financial analysis therefore requires a bottom-up view using ethanol production economics, specialty chemical pricing, excipient qualification and downstream formulation demand.

What is pharmaceutical excipient alcohol?

Pharmaceutical excipient alcohol is usually ethanol meeting a recognized pharmacopeial specification, such as USP-NF, Ph. Eur. or BP. It acts as a solvent, co-solvent, antimicrobial aid, extraction medium, penetration enhancer and processing agent.

The main pharmaceutical forms are:

Product type	Typical use	Commercial characteristic
Absolute or anhydrous ethanol	Solvent systems, extraction, manufacturing	Higher specification and price
Dehydrated ethanol	Oral liquids, topical products, process use	Sensitive to water content
Alcohol USP-NF	Finished pharmaceutical formulations	Requires documented quality and traceability
Alcohol Ph. Eur. or BP	European and international formulations	Requires compendial conformity
Denatured ethanol	Manufacturing and selected topical uses	Lower tax burden, restricted formulation use
Undenatured ethanol	Oral medicines and regulated products	Higher tax, diversion and compliance exposure

Ethanol should not be conflated with benzyl alcohol, isopropyl alcohol or cetyl alcohol. Those materials have different toxicology, formulation roles and regulatory profiles.

The U.S. Food and Drug Administration lists alcohol and related materials in its Inactive Ingredient Database for multiple routes and dosage forms. Inclusion in the database does not establish universal suitability at every concentration or for every patient population. Finished-product sponsors remain responsible for formulation safety and labeling compliance (FDA, 2024a).

How large is the pharmaceutical alcohol market?

No single public dataset isolates global pharmaceutical-grade ethanol revenue. Market reports commonly combine pharmaceutical, personal-care, food, industrial and fuel ethanol, producing estimates that are not directly comparable.

A more useful market structure is:

1. Fuel ethanol represents the largest volume segment.
2. Industrial ethanol represents a broad middle segment, including solvents, coatings, chemicals and cleaning products.
3. Pharmaceutical, cosmetic and high-purity ethanol represent smaller specialty segments with higher unit values.

The pharmaceutical excipient segment is therefore volume-light but qualification-intensive. A drug manufacturer may purchase only a small quantity relative to a fuel blender, yet require:

• Lot-level certificates of analysis.
• Compendial testing.
• Residual solvent controls.
• Denaturant verification.
• Elemental impurity controls.
• Change-control notification.
• Audit access.
• Reliable supply during regulatory or transport disruptions.

This creates a price premium over commodity ethanol. The premium varies by purity, packaging, documentation, geographic market and whether the supplier performs final purification and filling.

What drives demand for pharmaceutical excipient alcohol?

Oral liquid medicines

Ethanol is used as a co-solvent for poorly water-soluble active ingredients, flavors, preservatives and botanical extracts. Demand is linked to cough and cold medicines, oral drops, elixirs, tinctures and certain pediatric or geriatric formulations.

Regulatory pressure limits ethanol concentrations in products intended for children. Sponsors may replace ethanol with glycerin, propylene glycol, polyethylene glycol, surfactants or cosolvent combinations when safety, taste or labeling requirements make ethanol less attractive.

Topical and dermatological products

Topical solutions, sprays, antiseptics, rubs and dermatology products use ethanol for solvent performance, rapid evaporation and antimicrobial support. This segment has higher volume than many oral-liquid applications and benefits from continued demand for topical delivery systems.

Extraction and manufacturing

Pharmaceutical manufacturers use ethanol to extract botanical materials and to clean, crystallize or process intermediates. Manufacturing demand is less visible to end-market analysts because the ethanol may not appear in the finished product.

Drug delivery and specialty formulations

Ethanol is used in selected transdermal, buccal, nasal and aerosol systems. It can improve solubility or modify evaporation and permeation. These uses are formulation-specific and do not create a broad patent moat around ethanol itself.

How does the pharmaceutical alcohol market compare with competing excipients?

Excipient	Primary formulation role	Main advantage over ethanol	Main limitation
Ethanol	Solvent and co-solvent	Volatility, solvent power, antimicrobial contribution	Flammability, toxicity at high exposure, taste
Propylene glycol	Co-solvent and humectant	Low volatility and broad formulation utility	Dose-related tolerability concerns
Glycerin	Humectant and sweetener	Low volatility, favorable mouthfeel	Higher viscosity and weaker solvent power
Polyethylene glycol	Solvent and plasticizer	Broad molecular-weight range	Compatibility and route-specific concerns
Isopropyl alcohol	Cleaning and topical use	Strong solvency and rapid evaporation	Generally unsuitable for oral products
Benzyl alcohol	Preservative and solvent	Effective at low concentrations	Neonatal toxicity concerns and formulation limits

Ethanol competes most directly with propylene glycol and glycerin in oral liquids. Replacement is technically feasible in many products but can require reformulation, stability work, new toxicology assessment, packaging review and regulatory variation filings. These switching costs support recurring demand.

What is the financial trajectory for pharmaceutical-grade alcohol?

The financial trajectory has four phases:

2020: Disruption and extraordinary demand

The COVID-19 pandemic produced a sharp increase in demand for ethanol used in hand sanitizers and disinfectants. The FDA issued temporary guidance addressing the manufacture of alcohol-based hand sanitizers during supply shortages (FDA, 2020). Commodity ethanol producers, distillers and chemical suppliers entered or expanded the market.

This period generated abnormal price spreads, but much of the revenue was temporary. Pharmaceutical excipient suppliers benefited from qualification, packaging and documentation capabilities rather than only from bulk ethanol ownership.

2021-2022: Normalization and cost inflation

Sanitizer demand declined from pandemic peaks. Ethanol producers faced feedstock, energy, freight and labor inflation. In the United States, corn prices and natural-gas costs affected production economics. In Europe, energy prices had an especially large effect on operating margins for energy-intensive distillation and dehydration.

Specialty suppliers with validated pharmaceutical supply chains retained stronger pricing than bulk producers. The commercial advantage shifted from emergency availability to quality assurance and contract reliability.

2023-2024: Stable demand with margin pressure

Demand returned to normal pharmaceutical and personal-care patterns. Fuel ethanol remained the dominant price reference in the United States, while European and Asian markets reflected different feedstock, import and energy conditions.

Pharmaceutical ethanol pricing remained supported by:

• Qualification requirements.
• Limited tolerance for supply interruption.
• Documentation and audit costs.
• Small-container and specialty packaging.
• Regulatory controls on denatured and undenatured alcohol.

Margins remained vulnerable when commodity ethanol prices fell faster than specialty contracts reset. Distributors with inventory and repackaging capabilities could protect gross margin better than producers selling only bulk material.

2025 onward: Moderate growth, limited structural expansion

The likely base case is low- to mid-single-digit value growth for pharmaceutical ethanol, driven by generic medicines, topical products, contract manufacturing, biologics-process support and emerging-market healthcare production. Volume growth should remain modest because ethanol is a mature excipient and substitution is available.

Higher growth is more likely in specialty grades, certified low-impurity materials, sustainable ethanol and regional supply arrangements than in total pharmaceutical ethanol volume.

Which companies compete in pharmaceutical-grade alcohol?

The competitive field has three layers.

Integrated ethanol producers

Large ethanol producers, including Archer Daniels Midland, Valero, Green Plains and POET in the United States, primarily serve fuel and industrial markets. Their scale supports low-cost production, but pharmaceutical sales typically require additional purification, documentation, packaging and channel development.

European and Asian producers compete through sugarcane, grain, synthetic or other feedstock routes. Local market access can matter more than global production scale because alcohol is hazardous to transport and heavily regulated.

Specialty chemical and excipient distributors

Avantor, Merck, Thermo Fisher Scientific, Spectrum Chemical and other laboratory or pharmaceutical-material suppliers sell high-purity ethanol in controlled packaging and with detailed documentation. These businesses often earn higher gross margins through qualification, inventory, technical support and supply-chain services.

Regional pharmaceutical suppliers

Regional producers and distributors can compete effectively where customers require local warehousing, import compliance, excise-tax management or smaller pack sizes. Their competitive position is strongest in emerging markets with fragmented formulation manufacturing.

What regulatory requirements affect pharmaceutical alcohol?

Ethanol is subject to overlapping pharmaceutical, tax, excise, transportation, worker-safety and environmental rules.

In the United States, key controls include:

• USP-NF conformity where the drug specification requires it.
• FDA requirements for finished drug manufacturing under current good manufacturing practice.
• Alcohol excise and denaturation rules administered by the Alcohol and Tobacco Tax and Trade Bureau.
• Hazard communication and flammable-liquid controls.
• Transportation requirements for hazardous materials.
• State-level alcohol controls in some jurisdictions.

The FDA’s drug-manufacturing framework requires manufacturers to establish component specifications and control the identity, strength, quality and purity of materials used in drug production (FDA, 2024b).

The European market relies on European Pharmacopoeia requirements, EU good manufacturing practice and national controls governing alcohol taxation and movement. The United Kingdom uses British Pharmacopoeia requirements and separate post-Brexit regulatory processes.

A major commercial distinction is whether the product is denatured. Denatured ethanol can reduce tax exposure, but the denaturant may make it unsuitable for oral products, injectable products or other sensitive applications. The wrong grade can trigger reformulation, batch rejection or regulatory noncompliance.

What patents protect pharmaceutical excipient alcohol?

Ethanol itself has no meaningful modern composition-of-matter patent estate. The molecule is long established, widely produced and available from many sources.

IP protection may instead attach to:

• A drug formulation containing ethanol.
• A specific ethanol concentration range.
• A transdermal or topical delivery system.
• An extraction or purification process.
• A packaging system for flammable pharmaceutical solvents.
• A method of stabilizing a formulation containing ethanol.
• A combination of ethanol with a specific active ingredient or permeation enhancer.

These rights generally protect the finished formulation or manufacturing method, not ethanol as a commodity excipient. Patent exposure must therefore be assessed at the drug-product level.

How strong is the patent estate for ethanol as an excipient?

The standalone patent estate is weak. Commercial barriers arise from quality systems, validated manufacturing, regulatory documentation and supply reliability. A new entrant can produce ethanol, but becoming an approved pharmaceutical supplier can require customer audits, process validation, compendial testing and multiple successful commercial lots.

What manufacturing and IP barriers affect supply?

The principal barriers are operational rather than patent-based.

Feedstock and energy exposure

Ethanol cost depends on feedstock, fermentation yield, dehydration energy, utilities, water and freight. Grain-based producers face crop and commodity volatility. Sugarcane producers have different agricultural and energy exposures. Synthetic ethanol producers are exposed to petrochemical inputs and carbon pricing.

Purification and impurity control

Pharmaceutical use requires control of aldehydes, methanol, higher alcohols, benzene, nonvolatile residues, water and other impurities. The required specification depends on the compendium and use case.

Flammability and logistics

Ethanol requires dedicated storage, explosion-control measures, compliant transportation and careful packaging. These constraints favor suppliers with existing hazardous-material infrastructure.

Supplier qualification

Drug manufacturers often qualify multiple sites but do not change ethanol suppliers casually. A supplier change can require comparability data, stability review, change-control assessment and regulatory documentation.

What generic entry risks exist for medicines using ethanol?

Ethanol does not generally block generic entry. Generic risk is determined by the active ingredient, dosage form, formulation claims, method-of-use patents and regulatory exclusivity.

A generic manufacturer may replace ethanol with another solvent, but doing so can change:

• Dissolution.
• Bioavailability.
• Preservative performance.
• Taste and patient acceptability.
• Container compatibility.
• Spray or aerosol behavior.
• Stability.
• Microbial control.

For products with narrow formulation specifications, ethanol can create technical friction even when it does not create a legal barrier. Paragraph IV challenges would target patents listed for the drug product, not the excipient’s commodity supply status.

What is the FDA and Orange Book status of pharmaceutical alcohol?

Ethanol is not an FDA-approved drug product when sold as an excipient. It is a component used in approved or unapproved drug formulations, depending on the finished product.

The Orange Book lists approved drug products and applicable patent and exclusivity information. It does not operate as a standalone patent register for excipients. Ethanol-related risk must be reviewed through the patents and regulatory records associated with the finished medicine (FDA, 2024c).

FDA Inactive Ingredient Database entries can support formulation precedent, but they do not guarantee that a proposed concentration, route or patient population will be accepted without further evaluation.

What geographic markets offer the strongest growth?

North America

The United States has strong demand from generic manufacturers, consumer health products, topical medicines and contract manufacturers. The market is mature, but specialty-grade demand is supported by strict documentation and supplier qualification.

Europe

Europe has high pharmaceutical manufacturing density and strong pharmacopeial controls. Energy costs, excise rules and cross-border movement can materially affect margins. Suppliers with regional production or warehousing have an advantage.

India

India is a major generic-drug and pharmaceutical manufacturing base. Demand is supported by oral liquids, topical formulations, contract manufacturing and export production. Price competition is intense, while documentation and supply continuity remain important.

China

China has large chemical and pharmaceutical manufacturing capacity. Domestic supply, export regulation and local qualification standards shape market access. Specialty suppliers compete against lower-cost regional producers.

Latin America and Southeast Asia

These regions offer healthcare manufacturing growth but may have greater exposure to imports, currency fluctuations, port disruptions and local alcohol controls. Regional distribution capability can be a decisive advantage.

What licensing deals and commercial partnerships matter?

Ethanol itself is generally sold through supply contracts rather than pharmaceutical licensing agreements. Commercial arrangements usually include:

• Multi-year supply contracts.
• Preferred-vendor agreements.
• Toll purification.
• Contract manufacturing supply.
• Regional distribution rights.
• Customer-specific packaging.
• Dual-source qualification programs.

The more valuable relationship is often the quality agreement, which defines testing, deviations, audits, change notification and release procedures. That agreement can protect share of wallet even when the underlying molecule is generic and nonproprietary.

What is the outlook for revenue and investment exposure?

Revenue growth should be defensive rather than high-growth. The segment can produce stable cash flow when suppliers control procurement, maintain high asset utilization and sell into validated pharmaceutical channels.

The main upside drivers are:

• Growth in liquid and topical medicines.
• Increased outsourcing to contract manufacturers.
• Demand for certified high-purity and low-impurity grades.
• Supply-chain regionalization.
• Sustainable or lower-carbon ethanol premiums.
• Expansion of pharmaceutical production in India, China and Southeast Asia.

The main downside risks are:

• Commodity price declines.
• Ethanol substitution by propylene glycol or glycerin.
• Lower sanitizer demand.
• Excise-tax changes.
• Feedstock shortages.
• Energy-cost spikes.
• Regulatory rejection of nonconforming material.
• Customer insourcing or dual sourcing.
• Restrictions on alcohol-containing pediatric medicines.

Key Takeaways

• Pharmaceutical excipient alcohol is primarily USP-NF, Ph. Eur. or BP-grade ethanol.
• The market is mature, fragmented and difficult to measure through public company disclosures.
• Pharmaceutical demand is small relative to fuel ethanol but earns higher value through qualification and documentation.
• Ethanol has no meaningful standalone modern patent estate.
• Formulation, delivery-system and method-of-use patents can protect finished medicines containing ethanol.
• Financial performance is driven by feedstock, energy, logistics, excise rules and specialty-grade pricing.
• The strongest commercial moat is validated supply capability, not molecular IP.
• Growth should be moderate, with specialty grades and regional supply contracts outperforming commodity volume.
• Generic entry risk generally arises from the finished drug’s patents and regulatory exclusivity, not from ethanol.
• FDA Inactive Ingredient Database precedent does not replace product-specific formulation and regulatory review.

FAQs

Is ethanol a pharmaceutical excipient or an active ingredient?

Ethanol is usually an excipient when used as a solvent, co-solvent, extraction medium or antimicrobial aid. Its regulatory status depends on the finished product and intended use.

Can pharmaceutical ethanol be replaced with propylene glycol?

Often, but not automatically. Replacement can affect solubility, viscosity, taste, stability, preservative performance, absorption and container compatibility. The change may require formulation development and regulatory review.

Does pharmaceutical ethanol require USP certification?

A drug manufacturer may require USP-NF compliance when the product specification calls for it. Other products may use Ph. Eur., BP or an approved internal specification. The applicable standard is determined by the finished-product dossier and market.

Is pharmaceutical-grade ethanol more profitable than fuel ethanol?

It can earn a higher price per unit because of testing, packaging, qualification and documentation. Its total addressable volume is much smaller, and margins remain exposed to commodity ethanol and energy prices.

Are there biosimilar risks for ethanol-containing medicines?

Ethanol has no biosimilar pathway because it is a small-molecule excipient, not a biologic. Biosimilar risk applies to biologic drug products whose formulations may or may not contain ethanol.

References

1. Alcohol and Tobacco Tax and Trade Bureau. (2024). Industrial alcohol and denatured spirits. U.S. Department of the Treasury. https://www.ttb.gov

2. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe. https://www.edqm.eu

3. U.S. Food and Drug Administration. (2020). Temporary policy for preparation of certain alcohol-based hand sanitizer products during the public health emergency. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveIngredient

5. U.S. Food and Drug Administration. (2024b). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Part 211. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211

6. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files